First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference, Boston
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Nov. 10, 2026 at 11:30am ET
Jefferies Global Healthcare Conference, London
- Format – Presentation and one-on-one investor meetings
- Date and Time – Monday, Nov. 16, 2026 at 4:30pm GMT / 11:30am ET
UBS Global Biopharma Conference 2026, London
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Nov. 17, 2026 at 11:40am GMT / 6:40am ET
Piper Sandler 38th Annual Healthcare Conference, New York
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Dec. 1, 2026 at 1:30pm ET
9th Annual Evercore Healthcare Conference, Miami
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Dec. 2, 2026 at 12:30pm ET
Live webcasts of the presentation and fireside chats will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. Replays of the webcasts will be available for at least 30 days following the events.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.
Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States